List of Akynzeo drug patents

Akynzeo is owned by Helsinn Hlthcare.

Akynzeo contains Netupitant; Palonosetron Hydrochloride.

Akynzeo has a total of 11 drug patents out of which 0 drug patents have expired.

Akynzeo was authorised for market use on 10 October, 2014.

Akynzeo is available in capsule;oral dosage forms.

Akynzeo can be used as use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

The generics of Akynzeo are possible to be released after 25 September, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6297375 HELSINN HLTHCARE 4-phenyl-pyridine derivatives
Mar, 2023

(a month from now)

US10676440 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US9951016 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US10233154 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US10961195 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943515 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US8623826 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US8951969 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Dec, 2030

(7 years from now)

US9271975 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Sep, 2031

(8 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 10 October, 2014

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

Dosage: CAPSULE;ORAL

More Information on Dosage

Akynzeo is owned by Helsinn Hlthcare.

Akynzeo contains Fosnetupitant Chloride Hydrochloride; Palonosetron Hydrochloride.

Akynzeo has a total of 10 drug patents out of which 0 drug patents have expired.

Akynzeo was authorised for market use on 19 April, 2018.

Akynzeo is available in powder;intravenous, solution;intravenous dosage forms.

Akynzeo can be used as use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

Drug patent challenges can be filed against Akynzeo from April, 2022.

The generics of Akynzeo are possible to be released after 02 June, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11312698 HELSINN HLTHCARE Fosnetupitant chloride hydrochloride having improved stability
May, 2032

(9 years from now)

US9403772 HELSINN HLTHCARE 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
May, 2032

(9 years from now)

US9908907 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(9 years from now)

US8426450 HELSINN HLTHCARE Substituted 4-phenyl pyridines having anti-emetic effect
May, 2032

(9 years from now)

US10717721 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Dec, 2030

(7 years from now)

US8895586 HELSINN HLTHCARE Methods of treating emesis
May, 2032

(9 years from now)

US10208073 HELSINN HLTHCARE Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator
May, 2032

(9 years from now)

US10624911 HELSINN HLTHCARE Physiologically balanced injectable formulations of fosnetupitant
Jun, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: April, 2022

Market Authorisation Date: 19 April, 2018

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

How can I launch a generic of AKYNZEO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic